Dell Technologies Capital returned for a round that took the cancer diagnostics technology developer's overall funding to $52m.

Grifols has agreed to buy the remaining 56% of antibody drug developer GigaGen having invested $35m four years ago.

Johnson & Johnson Innovation – JJDC helped the eye drop developer close a series A round that will fund development of lead asset Brimochol.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.

Koch Disruptive Technologies has provided $110m for the drug discovery technology startup's series B round following a $190m first close in January.

The computational pathology technology provider has added $25m to a round co-led by Johnson & Johnson Innovation – JJDC.

Novo will exit the musculoskeletal disease drug developer, should the latter complete an initial public offering on the Nasdaq Global Market.

SR One is line for an exit from the small-molecule therapy developer, which has raised $170m in venture funding in the past year.

The immuno-oncology company, based on University of Turin research, has completed a $21m series B round led by Claris Ventures.